The Women's Health & Femtech Report Library.

Women spend 25% more life in poor health. Closing gap = 75M DALYs/yr, $1T GDP by 2040. Sizes endo treatment at $180-250B, menopause $120-350B.

Actionable blueprint for 9 conditions driving 1/3 of WH gap. Only 1% of R&D goes to non-cancer women's health.

Only 6% of private healthcare investment goes to WH. 90% concentrated in cancers/repro/maternal. $100B+ US opportunity in CVD, osteoporosis, menopause, Alzheimer's.

US-specific. OOP costs for employed women $15B/yr higher than men ($266 more per woman, 18%+ increase).

First-ever 10-year gov women's health strategy. Addresses gender health gap, research gaps, menopause, fertility, endo, maternal health.

Global roadmap: end preventable maternal/newborn/child deaths by 2030. 60 monitoring indicators.

Global/regional trends in reproductive, maternal, newborn, child, adolescent health & nutrition. LMIC focus.

Multi-year review of gender as health determinant. Policy recommendations for resources, opportunities, care.

43% of the female health burden comes from conditions standard WH frameworks don't track or fund.

Femtech VC surpassed $5B since 2020. $1.2B deployed in 2024. Flo $200M Series C, Maven $125M Series F.

2025 ed: WH VC hit $2.6B in 2024 (55% YoY). Biopharma share surged to 34% (from 12% in 2021). Healthtech fell 54%→38%.

2020-2024: US digital health WH startups raised $4.4B. $671M in 2024 = 6.6% of all digital health funding. 65% in fertility/pregnancy.

~3,970 femtech cos globally, 1,060 funded, $7.61B raised total. H1 2025: $158M across 35 rounds.

WH receives only 2% of healthcare VC. Only 5% of global R&D in 2020 went to WH. 1B women in menopause globally, 80-90% symptomatic.

$250M global open call. 4,000+ orgs from 119 countries. 80+ awardees ($1-5M each). Part of $1B commitment.

Advocacy/investment report. RAND-modeled ROI: $350M research investment yields $14B return (40:1) across 4 conditions (RA, CAD, Alzheimer's, lung cancer). Market $45.5B (2025) to $58B (2029). WH VC tripled since 2019 but still ~2.3% of healthcare VC. No original health economics — aggregates McKinsey, RAND, Deloitte. Launched at JPM Healthcare Conference.

Record femtech funding, but persistent structural ceilings — mid-2026 read.

Women's health funding fell ~56% to $478M as capital concentrated in fewer, more mature companies.

763 FemTech cos analyzed. Market $500M-$1B at publication. $2.5B funding by Dec 2021. FemTech = 3% of digital health funding.

Biopharma commercial opportunities in underserved women's health conditions.

Gender health gap + investment opportunity. Only ~15% of research funding historically to female-specific diseases. VC tripled 2019-2024.

Broader gender-lens investing including WH as investment theme.

50% of women skip/delay care. Women 35% more likely to forgo care than men. 'Triple threat' of cost, access, negative experience.

Digital health declined overall 2022-23 but WH funding increased to $481M in 2023.

Gender health gap in usage rates, costs, quality of care. Tech startup landscape analysis.

$39.29B (2024) → $97.25B (2030). CAGR 16.37%. Devices 33%, D2C 31%, North America 46% share.

$9.12B (2025) → $41.14B (2034). CAGR 18.37%.

$60.89B (2025) → $140.64B (2035). CAGR 8.73%.

$6.9B (2023) → $26.1B (2033). CAGR 15.2%. 20 countries covered.

$8.56B (2025) → $16.78B (2030). CAGR 14.42%.

Exceeded $60.2B (2024). CAGR 16% through 2034.

Projected $266.99B by 2035. Menopause solutions as key growth driver.

CAGR 13.52% by 2030.

CAGR 13.52% by 2030.

Global sizing with demand forecast to 2031.

OG landmark report. $50B market potential by 2025. 50% of global pop as target market.

5 CSFs: accessibility in dev countries, gov policy, B2B hospital partnerships, revenue models, affordability. *Press release free.

Femtech cos worth $28B in 2023, 17.4% CAGR to 2030. *Press release free.

146K respondents, 142 countries. Yr 4: cancer testing declined for first time (only 10%). Women struggling with basic needs worst in ~20 yrs.

Not exclusively health but includes mental health, stress, workplace data. 2025: 7,500 women, 15 countries. 51% rate mental health as good.

£1 invested in O&G → £11 ROI per woman. Period/endo/fibroid absenteeism = £11B/yr. Menopause unemployment = £1.5B/yr (60K women).

Cross-sectional survey, n=32,748 Dutch women. 14% absenteeism, 81% presenteeism due to menstrual symptoms. Mean 1.3 days lost/cycle. Foundational productivity study.

US claims analysis. Per-patient direct costs ~$13,400/yr for endo. Indirect costs via absenteeism and short-term disability. Quality A source.

First application of Stromberg multipliers (A=0.97, P=0.54, WEP=0.72) to endo productivity costs. Introduces WEP decomposition and DAC methodology. NZ population-level estimates.

Survey of self-management in endo. Heat therapy most used, cannabis/CBD emerging. Informs patient decision aids and allied health pathways.

Pooled prevalence of menstrual-related absenteeism: 15% across 673,380 women/girls aged 15-49 in 44 countries. Highest: South Asia (20%), West/Central Africa (18.5%). Cross-sectional analysis of MICS surveys.

10 subsectors tracked. Longevity subsector = $2.6B (2021). 58% of femtech longevity cos US-based. Dashboard free, deep reports paywalled.

TECH framework ranking. 95+ cos mapped. Projected $50B by 2025, $100B by 2030. Fertility to menopause.

Dedicated femtech/WH market reports and analysis.

Intersection of social inequality, cancer risk and outcomes for women.

Academic analysis of femtech from innovation toward health equity.

Critical conceptual review of femtech as a category. Useful for framing/definitions.

US federal WH research priorities. Only 8.8% of NIH budget 2013-2023 went to women's health research.

FDA agenda for advancing women's health through regulatory science.

Lancet Comment, Vol 407, 7 March 2026. 81% presenteeism + 14% absenteeism from menstrual symptoms (cites Schoep 2019, n=32,748). 15% pooled menstrual absenteeism across 44 LMIC countries (Starr et al. 2025). 1% of pharma R&D budget to female-specific disorders. 9% of VC to FemTech. 5-12 year diagnostic delay for endo/adenomyosis. Advocates for ultrasound training in gyn curricula.

13-page investment thesis. Women = 47% of US workforce, make 80% of healthcare decisions, spend 18% more OOP. $100B+ exit value across 276 transactions (2000-2024). 27 billion-dollar exits. 2024 = $21.4B exit year. Diagnostics 17.6x capital efficiency. Maternal health 26x capital efficiency. Median exit $238M. 76% of exits in conditions exclusive to women but = only 5% of female disease burden. Life-course lens: adolescence → reproductive → peri/menopause → later life. OB/GYN shortage: 22,000 by 2030. 12.4-year healthspan-lifespan gap. Chronic pain costs US $723B annually. Closing healthspan gap = equivalent of adding 137M women to full-time workforce by 2040. Autoimmune: 80% of patients are women. Osteoporosis: 4x higher risk in women ≥50. Alzheimer’s: 2/3 of US cases are women.

145,000 people surveyed across 144 countries. Released March 17, 2026. 1.5 billion women were NOT tested for cancer, high blood pressure, diabetes, or STIs in the past year. Testing at highest since tracking began (2020): 39% tested for high blood pressure, 24% diabetes, 13% cancer. But 54% of women worldwide had NO screening. 1/3 of women report daily physical pain. Nearly 1 in 4 report health problems interfering with daily activities. 67% feel safe walking alone at night (up from 63%). Gains concentrated in older women in wealthier countries — low-income nations flat.

December 2025. Five focus countries: Indonesia, Philippines, Singapore, Thailand, Vietnam. Startups grew from 39 (2021) to 93 (2024) — more than doubled. Consumer spending on femtech in SEA reached $6 billion in 2024. 58% of women in region currently using femtech products/services. 75%+ of femtech companies founded 2019-2024. Only 21% of femtech cos in SEA have secured external funding. $32.9M invested in femtech across five countries (2019-2024) — 96% went to Singapore-headquartered companies. Six strategic recommendations.

Comprehensive exit database: 276 transactions (2000–2024), $100B+ total exit value. $21.4B in 2024 alone. 27 billion-dollar exits. Covers M&A and IPO across all women's health verticals. Median exit $238M. 76% of exit value in conditions exclusive to women. Diagnostics 17.6x capital efficiency. Maternal health 26x capital efficiency. Primary source for Health2047 investment thesis.

March 12, 2026. Global WH market $430-440B (2025), projected $600B+ by 2030 (6-8% CAGR). Core WH segment (gyn, oncology) $195-205B, projected $270-280B by 2030. ~5% of healthcare R&D funding to WH (cites WEF). ~$60B private capital deployed 2020-2025. Menopause funding growing ~13% annually. Pharma 8-10%/yr growth; consumer health tech 14-17%/yr. High-growth areas: oncology, menopause, autoimmune, CVD/neurodegenerative.

June 2024. First report to quantify consumer femtech value per SEA market. SEA femtech consumer market $6B with estimated 5% spending increase near-term. Covers 6 countries: Indonesia, Malaysia, Singapore, Thailand, Philippines, Vietnam. Topics: awareness, usage patterns, spending habits, maternal/reproductive health, menopause. Next version releasing June 2026.